Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma (Q41688961)

7 October 2017

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma (English)

1 reference

7 October 2017

anti-retroviral agent

0 references

author

Anne-Geneviève Marcelin

28

object named as

Anne-Geneviève Marcelin

1 reference

7 October 2017

Philippe Flandre

27

0 references

Stéphanie Haïm-Boukobza

20

object named as

Stéphanie Haïm-Boukobza

1 reference

7 October 2017

14

Sabine Yerly

1 reference

7 October 2017

2

Diane Descamps

1 reference

7 October 2017

11

Stéphanie Raymond

1 reference

7 October 2017

7

Constance Delaugerre

1 reference

7 October 2017

5

Mary-Anne Trabaud

1 reference

7 October 2017

13

Chakib Alloui

1 reference

7 October 2017

9

Francis Barin

1 reference

7 October 2017

17

Anne Signori-Schmuck

1 reference

7 October 2017

23

Sophie Vallet

1 reference

7 October 2017

8

Brigitte Montes

1 reference

7 October 2017

4

Véronique Schneider

1 reference

7 October 2017

15

Coralie Pallier

1 reference

7 October 2017

25

Lambert Assoumou

1 reference

7 October 2017

22

Anne Maillard

1 reference

7 October 2017

1

Cathia Soulie

1 reference

7 October 2017

16

Sandrine Reigadas

1 reference

7 October 2017

21

Audrey Mirand

1 reference

7 October 2017

12

Hélène Jeulin

1 reference

7 October 2017

24

Catherine Roussel

1 reference

7 October 2017

3

Maxime Grudé

1 reference

7 October 2017

18

Aurélie Guigon

1 reference

7 October 2017

19

Samira Fafi-Kremer

1 reference

7 October 2017

10

Virginie Ferre

1 reference

7 October 2017

Laurence Morand-Joubert

6

1 reference

7 October 2017

Vincent Calvez

26

1 reference

7 October 2017

ANRS Resistance AC11 Group

29

1 reference

7 October 2017

language of work or name

English

0 references

publication date

25 October 2014

1 reference

Journal of Antimicrobial Chemotherapy

7 October 2017

1 reference

7 October 2017

70

1 reference

7 October 2017

566-572

1 reference

7 October 2017

2

1 reference

Antiretroviral therapy and central nervous system HIV type 1 infection

7 October 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Changing incidence of central nervous system diseases in the EuroSIDA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Emergence of raltegravir-resistant HIV-1 in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Raltegravir resistance in the cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU419

21 January 2018

Identifiers

DOI

10.1093/JAC/DKU419

1 reference

7 October 2017

1 reference